5 results for “bladder carcinoma”

Set a search alert

Research ArticleOpen accessPhrase in the titleRole of IL-10 in Urinary Bladder Carcinoma and Bacillus Calmette-Guerin ImmunotherapyYi Luo, Eric J. Askeland, Mark R. Newton, Michael A. O’DonnellProblem statement: Bladder cancer is a common urologic cancer and intravesical Mycobacterium bovis Bacillus Calmette-Guerin (BCG) is the mainstay in the treatment of superficial bladder cancer. However, the current BCG therapy is not desirable with respect to its efficacy and side effects. Interleukin (IL)-10, a T helper type (Th) 2 cytokine, plays an important regulatory role in bladder cancer immunosurveillance … …American Journal of Immunology, Vol. 8, Issue 1 · 9 Mar 2012 · 8,005 accessesView PDF Cite

Research ArticleOpen accessEvery word in the titleInvestigations in the molecular events of Transitional Cell Carcinoma of the BladderH.S. Kadhim, A.S. Abdulamir, R.R. Hafidh et al.Problem Statement: Transitional Cell Carcinoma (TCC) of the bladder is a significant health problem worldwide. The molecular mechanisms of tumor development and progression are complicated but likely involve the interaction of tumor suppressor genes, oncogenes, cell cycle regulatory proteins and other factors. Hence this study tries to explore the role of p53, bcl-2, c-myc and Ki-67 in TCC of the … …American Journal of Biochemistry and Biotechnology, Vol. 4, Issue 4 · 31 Dec 2008 · 7,528 accessesView PDF Cite

Research ArticleOpen accessEvery word in the titleSelective Susceptibility of Human Bladder Transitional Cell Carcinoma T24 Cells towards NBD PeptideSankari Durairajan, Charles Emmanuel Jebaraj Walter, Kalaiselvi Periyandavan et al.Bladder cancer is a recurrent disease that often develops chemoresistance and is on the rise in developing countries. After diagnosis surgery followed by immunotherapy and/or chemo- radiation therapy are the available treatments. These treatments do not provide protection against disease progression or recurrence thus highlighting the need to identify and develop drugs that are capable of inhibiting bladder cancer. T24 … …American Journal of Biochemistry and Biotechnology, Vol. 16, Issue 2 · 20 Apr 2020 · 7,787 accessesView PDF Cite

Research ArticleOpen accessIn the keywordsThe Phenotypically Suppressed Cancer Cell As a Therapeutic TargetKimberly D. Kyker, Jessica E. Thorpe, Satyendra S. Shenoy et al.Bladder cancer recurs in up to 70% of patients judged to be tumor-free after treatment. Like other cancers, delayed appearance of metastases is common. These findings suggest the malignant phenotype can be suppressed, to emerge later. Following up on previous research in our laboratory showing that normal extracellular matrix can suppress the malignant phenotype of bladder cancers, we here demonstrate … …American Journal of Pharmacology and Toxicology, Vol. 1, Issue 4 · 31 Dec 2006 · 6,471 accessesView PDF Cite

Research ArticleOpen accessAll words, across the recordRole of Progranulin Gene Expression as a Molecular Biomarker for Bladder CancerSalwa M. Abo El-khair, Mie A. Mohamed, Tamer E. AlkhiaryBladder cancer is the second most common cancer of the urinary system. Early diagnosis of this tumor and estimation of risk of future progression has a significant impact on prognosis. Although there are several molecular markers for the diagnosis and prognosis for this tumor, their accuracy is not ideal. Progranulin is a growth factor that may play a critical role … …American Journal of Biochemistry and Biotechnology, Vol. 8, Issue 2 · 22 Jun 2012 · 7,699 accessesView PDF Cite